Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Human immunodeficiency virus type 1 (HIV-1) isolates of 8 Ethiopian and 8 Swedish untreated AIDS-patients were examined for their sensitivity to 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI) and leukocyte-derived interferon-alpha (IFN-alpha). No significant difference in drug sensitivity was found between Ethiopian and Swedish isolates, which all were sensitive to AZT, ddI and IFN-alpha except for one Swedish isolate. This isolate exhibited a mutation at amino acid position 215. These results suggest that it should be possible to perform clinical trials in Ethiopia using the same dose regimens as in Sweden.
D000163:Acquired Immunodeficiency Syndrome / Q000382:microbiology*; D016049:Didanosine / Q000494:pharmacology*; D005002:Ethiopia; D016655:HIV Core Protein p24 / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects; D013548:Sweden; D015215:Zidovudine / Q000494:pharmacology*
D016655:HIV Core Protein p24; D016898:Interferon-alpha; D015215:Zidovudine; D012194:RNA-Directed DNA Polymerase; D016049:Didanosine